Skip to main content

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

Abstract

Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32–72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators (2013) PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New Engl J Med 369:1783–1796

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Cortes JE, Kim DW, Pinilla-Ibarz J, et al (2014) Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 124: abstract 3135

  3. 3.

    Poch Martell M, Sibai H, Deotare U, Lipton JH (2016) Ponatinib in the therapy of chronic myeloid leukemia. Exp Rev Hematol 9:923–932

    Article  CAS  Google Scholar 

  4. 4.

    Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M (2017) Identification, prevention and management of cardiovascular risk in chronic myeloid leukemia patients candidate to ponatinib: an expert opinion. Ann Hematol 96:549–558

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    Muller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G (2017) Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol 120:52–59

    Article  PubMed  Google Scholar 

  6. 6.

    Breccia M, Abruzzese E, Iurlo A, Gozzini A, Isidori A, Gangemi D, Pregno P, Alimena G (2016) Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. Haematologica 101:e267–e268

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. 7.

    Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J (2015) Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica 100(suppl 1):e495

    Google Scholar 

  8. 8.

    Hochhaus A, Pinilla-Ibarz J, Kim DW, et al (2014) Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. J Clin Oncol 32(15, suppl): abstract 708

Download references

Author information

Affiliations

Authors

Contributions

MB designed the study, analyzed the data, and wrote the manuscript; EA, AG, AI, PP, AI, DG, MG, MBo, FC, FS, LL, MBoc, DL, AM, NG, MC, IC, MP, and ARS collect data; RF critically revised the paper and approved the final version.

Corresponding author

Correspondence to Massimo Breccia.

Ethics declarations

Conflict of interest

MB received honoraria for speaking by Incyte, Pfizer, Novartis, and BMS.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Breccia, M., Abruzzese, E., Castagnetti, F. et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol 97, 1577–1580 (2018). https://doi.org/10.1007/s00277-018-3337-2

Download citation

Keywords

  • Chronic myeloid leukemia
  • Ponatinib
  • Second line
  • Prognosis